Liver disease has emerged as the most common non-AIDS-related cause of death in HIV patients. However, there is limited data\nregarding this condition including our setting in Ethiopia. Hence, liver enzyme abnormalities among highly active antiretroviral\ntherapy (HAART) experienced and HAART naÃ?¨Ã?±ve patients were assessed in this study. A total of 164 HAART experienced and 164\nHAART naÃ?¨Ã?±ve patients were studied. Blood specimen was collected to determine alanine aminotransferase (ALT) and aspartate\naminotransferase (AST), CD4 count, and viral hepatitis. The prevalence of liver enzyme abnormality was 20.1% and 22.0% among\nHAART experienced and HAART naÃ?¨Ã?±ve patients, respectively. The HAART experienced patients had higher mean ALT than\nHAART naÃ?¨Ã?±ve patients (P = 0.002). Viral hepatitis (AOR = 6.02; 95% CI = 1.87ââ?¬â??19.39), opportunistic infections (AOR = 2.91;\n95% CI = 1.04ââ?¬â??8.19), current CD4 count <200 cells/mm3 (AOR = 2.16; 95% CI = 1.06ââ?¬â??4.39), and male sex (AOR = 1.83; 95% CI =\n1.001ââ?¬â??3.33) were associated with elevated ALT and/or AST. In conclusion, liver enzyme abnormalities were high in both HAART\nexperienced and HAART naÃ?¨Ã?±ve HIV-1 infected patients. Hence, monitoring and management of liver enzyme abnormalities in\nHIV-1 infected patients are important in our setting.
Loading....